… Gefitinib and erlotinib are the first-line tyrosine kinase inhibitors (TKI) for advanced non-…
However, co-administration of either drug with proton pump inhibitors (PPI) or histamine-2 …

… NSCLC treated with gefitinib or erlotinib [31]. For these reasons, our analysis evaluated the
effect of PPIs, a type of ARA with the highest probability of having an effect on survival, if any. …

… lung cancer patients treated with erlotinib (negative impact on 1 … of 544 NSCLC patients
treated with erlotinib, 124 received … or H2 blockers and gefitinib (4340 patients) or erlotinib (1635 …

… CYP3A4 inhibitors and inducers, proton pump inhibitors (PPIs), … concentrations of gefitinib
and erlotinib were markedly … plasma concentration (Cmax) of gefitinib decreased by 66 and 30…

… These interactions translate into major clinical impacts, with demonstrated loss of efficacy
for some TKIs (erlotinib, gefitinib, pazopanib), and conflicting results with many other oral drugs…

… erlotinib (150 mg/day) is its maximum tolerated dose. Citation13 Besides, compared with
gefitinib, exposure to erlotinib … Citation14 Therefore, we assume that the effects of gefitinib are …

… Patients with NSCLC treated with gefitinib or erlotinib for at least 1 week between January
2009 and October 2021 were enrolled and divided into four groups based on the presence/…

… receiving first-generation EGFR TKIs (erlotinib and gefitinib). The clinical effect of AS on …
the use of 1st generation EGFR TKIs (erlotinib and gefitinib) as initial treatment is still ubiquitous …

… This type of drug-drug interaction may have detrimental effects on efficacy, with major
clinical impacts described for some orally administrated targeted therapies (erlotinib, gefitinib, …

… Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 …
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors—erlotinib and gefitinib. …